Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
General11 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News17 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General23 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
General13 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery